Skip to main content
Premium Trial:

Request an Annual Quote

Veridex to Acquire Assets of Immunicon for $31M

NEW YORK (GenomeWeb News) – Johnson & Johnson company Veridex said today that it will acquire substantially all of the assets of cancer diagnostics firm Immunicon for $31 million in cash.
The assets involved in the sale include intellectual property, product inventory, clinical data, and all technologies related to Immunicon’s CellSearch system, which automates the detection and enumeration of circulating tumor cells. The system is currently cleared for the prognosis and monitoring of patients with metastatic breast, metastatic colorectal, and metastatic prostate cancer.
Immunicon is currently in bankruptcy proceedings, and the bankruptcy court overseeing its case must approve the deal. Veridex said that the acquisition price is subject to certain closing adjustments, plus the discharge and release of certain claims owed to Veridex, and the assumption of certain liabilities.
The firms have been collaborators since 2000 in developing cancer diagnostic platforms and products.
In addition to selling CellSearch assays, Veridex also sells GeneSearch assays that use molecular technology.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.